Novartis, Amgen and Banner Alzheimer’s Institute Terminate Two P-II/III Studies of CNP520 (umibecestat) for the Prevention of Alzheimer’s Disease

 Novartis, Amgen and Banner Alzheimer’s Institute Terminate Two P-II/III Studies of CNP520 (umibecestat) for the Prevention of Alzheimer’s Disease

Novartis, Amgen and Banner Alzheimer’s Institute Terminate Two P-II/III Studies of CNP520 (umibecestat) for the Prevention of Alzheimer’s Disease

Shots:

  • Novartis, Amgen and Banner Alzheimer’s Institute discontinue two P-II/III studies evaluating the safety & efficacy of CNP520 for the prevention or the delay of the onset of Alzheimer’s disease due to lack of efficacy and worsening of cognitive function in the patients
  • In Aug’2015, Amgen & Novartis collaborated to develop & commercialize therapies for migraine & Alzheimer’s disease, sponsored by both the companies in collaboration with Banner Alzheimer’s Institute
  • CNP520 (PO) is a BACE (aspartyl protease) inhibitor designed to reduce Aβ production to prevent or treat Alzheimer’s disease

Click here to read full press release/ article | Ref: Novartis | Image: Novartis

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post